G. Müzes

发表

Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients

Z. Tulassay, P. Lakatos, P. Miheller, 2009, Inflammatory bowel diseases.

Effect of free radical scavengers on superoxide dismutase (SOD) enzyme in patients with alcoholic cirrhosis.

K. Nékám, J. Féher, G. Deák, 1988, Acta medica Hungarica.

Effect of the natural bioflavonoid antioxidant silymarin on superoxide dismutase (SOD) activity and expression in vitro.

J. Féher, L. Prónai, G. Deák, 1993, Biotechnology therapeutics.

Hepatoprotective and immunomodulatory effects of antioxidant therapy.

K. Nékám, J. Féher, P. Gergely, 1988, Acta medica Hungarica.

Effect of silibinin and vitamin E on restoration of cellular immune response after partial hepatectomy.

J. Féher, A. Blázovics, P. Gergely, 2001, Journal of ethnopharmacology.

Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy

Z. Tulassay, K. Rácz, P. Lakatos, 2007 .

Infliximab Therapy Improves the Bone Metabolism in Fistulizing Crohn’s Disease

T. Zágoni, Z. Tulassay, K. Rácz, 2006, Digestive Diseases.

Drug-related Churg-Strauss syndrome?

Z. Tulassay, A. Somogyi, G. Müzes, 1998, Adverse drug reactions and toxicological reviews.

Is the efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in different behavior types of Crohn's disease?

F. Nagy, T. Wittmann, T. Molnár, 2008, Journal of Crohn's & colitis.

[Effect of silimarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind protocol)].

K. Nékám, J. Féher, G. Deák, 1990, Orvosi hetilap.

Depressed monocyte production of interleukin-1 and tumor necrosis factor-alpha in patients with alcoholic liver cirrhosis.

J. Féher, P. Gergely, G. Deák, 2008, Liver.

Effect of the bioflavonoid silymarin on the in vitro activity and expression of superoxide dismutase (SOD) enzyme.

K. Nékám, J. Féher, P. Gergely, 1991, Acta physiologica Hungarica.

[Liver-protective action of silymarin therapy in chronic alcoholic liver diseases].

K. Nékám, J. Féher, G. Műzes, 1989, Orvosi hetilap.

Identification of familial Mediterranean fever (FMF) in a Gypsy woman: a case report.

E. Ben-Chetrit, É. Nagy, P. Magyar, 2007, Clinical and experimental rheumatology.

Antinucleosome Antibodies and Decreased Deoxyribonuclease Activity in Sera of Patients with Systemic Lupus Erythematosus

P. Gergely, E. Nagy, K. Sallai, 2005, Clinical Diagnostic Laboratory Immunology.

[Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases].

K. Nékám, J. Féher, P. Gergely, 1990, Orvosi hetilap.

Effect of silibinin on the activity and expression of superoxide dismutase in lymphocytes from patients with chronic alcoholic liver disease.

K. Nékám, J. Féher, G. Műzes, 1987, Free radical research communications.

Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers.

K. Nékám, J. Féher, P. Gergely, 1990, The Italian journal of gastroenterology.

Inflammasome, inflammation and cancer: an interrelated pathobiological triad.

F. Sipos, G. Müzes, 2015, Current drug targets.

Effect of (+)cyanidanol-3 on cellular immune reactions and on superoxide dismutase activity in vitro.

K. Nékám, J. Féher, A. Perl, 1987, Free radical research communications.

The insulin-like growth factor system: IGFs, IGF-binding proteins and IGFBP-proteases.

J. Féher, G. Műzes, G. Müzes, 2005, Acta physiologica Hungarica.